Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Pratt

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|July 18, 2015
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt, et al.
Haematologica|April 5, 2015
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidantsAngelo Agathanggelou, Victoria J Weston, Tracey Perry, et al.
Haematologica|January 18, 2020
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2Phillip L R Nicolson, Sophie H Nock, Joshua Hinds, et al.
The Lancet. Oncology|November 1, 2019
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T Drayson, Stella Bowcock, Tim Planche, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Science Translational Medicine|September 20, 2013
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemiaMark Cobbold, Hugo De La Peña, Andrew Norris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep SequencingMarina Parry, Matthew Jj Rose-Zerilli, Viktor Ljungström, et al.
American Journal of Hematology|March 3, 2023
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosingSuzanne O Arulogun, Duncan Brian, Harshita Goradia, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|July 18, 2015
Optimizing the management of patients with spinal myeloma diseaseSean Molloy, Maggie Lai, Guy Pratt, et al.
Haematologica|April 5, 2015
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidantsAngelo Agathanggelou, Victoria J Weston, Tracey Perry, et al.
Haematologica|January 18, 2020
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2Phillip L R Nicolson, Sophie H Nock, Joshua Hinds, et al.
The Lancet. Oncology|November 1, 2019
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T Drayson, Stella Bowcock, Tim Planche, et al.
Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.
British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.
Science Translational Medicine|September 20, 2013
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemiaMark Cobbold, Hugo De La Peña, Andrew Norris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep SequencingMarina Parry, Matthew Jj Rose-Zerilli, Viktor Ljungström, et al.
American Journal of Hematology|March 3, 2023
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosingSuzanne O Arulogun, Duncan Brian, Harshita Goradia, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
Pageof 14